Should Journal Editors Play Science Cops?

The two principal Charles Bluestone and Erdem Cantekin, key members of a group, that began a major clinical trial in 1981 to measure the efficacy of drugs used to treat diseases in the middle ear in children. Bluestone, an otolaryngologist, is director of the Otitis Media Research Center and principal investigator on the $5.6 million NIH grant that supported the work at Children's Hospital. Cantekin, a biomedical engineer was the center's director of research. Cantekin, whose paper remains unp

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The two principal Charles Bluestone and Erdem Cantekin, key members of a group, that began a major clinical trial in 1981 to measure the efficacy of drugs used to treat diseases in the middle ear in children. Bluestone, an otolaryngologist, is director of the Otitis Media Research Center and principal investigator on the $5.6 million NIH grant that supported the work at Children's Hospital. Cantekin, a biomedical engineer was the center's director of research.

Cantekin, whose paper remains unpublished, told a congressional panel September 27 that research at the center is being distorted by the fact that the center recieves funding from several drug companies. He added that certain find- ings made by the research team are seriously flawed. His analysis of the same data attempts to show that the drugs tested are no more effective in clearirg up the disease than is no treatment at all. A University of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies